Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。